Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ABHD14B

Gene summary for ABHD14B

Gene summary.

Gene information	Species	Human
	Gene symbol	ABHD14B
	Gene ID	84836
	Gene name	abhydrolase domain containing 14B
	Gene Alias	CIB
	Cytomap	3p21.2
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	Q96IU4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
84836	ABHD14B	P127T-E	Human	Esophagus	ESCC	1.49e-22	3.34e-01	0.0826
84836	ABHD14B	P128T-E	Human	Esophagus	ESCC	2.71e-32	9.46e-01	0.1241
84836	ABHD14B	P130T-E	Human	Esophagus	ESCC	1.19e-48	9.35e-01	0.1676
84836	ABHD14B	S43	Human	Liver	Cirrhotic	6.64e-06	-1.52e-01	-0.0187
84836	ABHD14B	HCC1_Meng	Human	Liver	HCC	1.11e-81	3.16e-01	0.0246
84836	ABHD14B	HCC2_Meng	Human	Liver	HCC	1.71e-35	8.32e-02	0.0107
84836	ABHD14B	cirrhotic1	Human	Liver	Cirrhotic	1.33e-07	2.12e-01	0.0202
84836	ABHD14B	cirrhotic2	Human	Liver	Cirrhotic	6.84e-08	2.75e-01	0.0201
84836	ABHD14B	HCC1	Human	Liver	HCC	5.29e-08	4.05e+00	0.5336
84836	ABHD14B	Pt13.b	Human	Liver	HCC	2.61e-16	2.24e-01	0.0251
84836	ABHD14B	Pt14.a	Human	Liver	HCC	6.28e-05	4.68e-01	0.0169
84836	ABHD14B	S014	Human	Liver	HCC	8.26e-29	1.30e+00	0.2254
84836	ABHD14B	S015	Human	Liver	HCC	5.71e-25	1.35e+00	0.2375
84836	ABHD14B	S016	Human	Liver	HCC	1.29e-29	1.27e+00	0.2243
84836	ABHD14B	S027	Human	Liver	HCC	1.79e-07	1.12e+00	0.2446
84836	ABHD14B	S028	Human	Liver	HCC	4.28e-29	1.61e+00	0.2503
84836	ABHD14B	S029	Human	Liver	HCC	1.39e-26	2.06e+00	0.2581
84836	ABHD14B	C04	Human	Oral cavity	OSCC	2.94e-09	7.28e-01	0.2633
84836	ABHD14B	C21	Human	Oral cavity	OSCC	4.88e-15	6.03e-01	0.2678
84836	ABHD14B	C30	Human	Oral cavity	OSCC	1.61e-31	1.26e+00	0.3055

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0009150	Colorectum	AD	purine ribonucleotide metabolic process	142/3918	368/18723	4.29e-15	1.17e-12	142
GO:0006163	Colorectum	AD	purine nucleotide metabolic process	149/3918	396/18723	1.08e-14	2.80e-12	149
GO:0072521	Colorectum	AD	purine-containing compound metabolic process	153/3918	416/18723	4.34e-14	1.01e-11	153
GO:0009259	Colorectum	AD	ribonucleotide metabolic process	144/3918	385/18723	5.25e-14	1.13e-11	144
GO:0019693	Colorectum	AD	ribose phosphate metabolic process	145/3918	396/18723	3.01e-13	5.71e-11	145
GO:0009117	Colorectum	AD	nucleotide metabolic process	168/3918	489/18723	2.20e-12	3.36e-10	168
GO:0006753	Colorectum	AD	nucleoside phosphate metabolic process	169/3918	497/18723	4.99e-12	6.98e-10	169
GO:0006790	Colorectum	AD	sulfur compound metabolic process	101/3918	339/18723	6.46e-05	1.07e-03	101
GO:0033865	Colorectum	AD	nucleoside bisphosphate metabolic process	42/3918	128/18723	1.12e-03	1.02e-02	42
GO:0033875	Colorectum	AD	ribonucleoside bisphosphate metabolic process	42/3918	128/18723	1.12e-03	1.02e-02	42
GO:0034032	Colorectum	AD	purine nucleoside bisphosphate metabolic process	42/3918	128/18723	1.12e-03	1.02e-02	42
GO:0034035	Colorectum	AD	purine ribonucleoside bisphosphate metabolic process	11/3918	21/18723	1.43e-03	1.22e-02	11
GO:0050427	Colorectum	AD	3'-phosphoadenosine 5'-phosphosulfate metabolic process	11/3918	21/18723	1.43e-03	1.22e-02	11
GO:00061631	Colorectum	SER	purine nucleotide metabolic process	109/2897	396/18723	4.26e-10	5.44e-08	109
GO:00091501	Colorectum	SER	purine ribonucleotide metabolic process	103/2897	368/18723	4.69e-10	5.68e-08	103
GO:00725211	Colorectum	SER	purine-containing compound metabolic process	113/2897	416/18723	4.80e-10	5.68e-08	113
GO:00092591	Colorectum	SER	ribonucleotide metabolic process	104/2897	385/18723	3.27e-09	3.04e-07	104
GO:00196931	Colorectum	SER	ribose phosphate metabolic process	105/2897	396/18723	8.15e-09	7.14e-07	105
GO:00091171	Colorectum	SER	nucleotide metabolic process	122/2897	489/18723	2.50e-08	1.76e-06	122
GO:00067531	Colorectum	SER	nucleoside phosphate metabolic process	122/2897	497/18723	6.64e-08	4.33e-06	122

Page: 1 2 3 4 5 6

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ABHD14B

SNV

Missense_Mutation

novel

c.518N>G

p.Lys173Arg

p.K173R

Q96IU4

protein_coding

tolerated(0.99)

benign(0.056)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

rs575308151

c.65G>A

p.Arg22Gln

p.R22Q

Q96IU4

protein_coding

deleterious(0)

probably_damaging(0.953)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

rs751636953

c.403N>A

p.Ala135Thr

p.A135T

Q96IU4

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-B5-A3FA-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

rs199563943

c.241N>T

p.Pro81Ser

p.P81S

Q96IU4

protein_coding

tolerated(0.13)

benign(0.003)

TCGA-D1-A1O7-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

c.125G>A

p.Arg42His

p.R42H

Q96IU4

protein_coding

tolerated(0.08)

benign(0.03)

TCGA-E6-A1LX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

novel

c.80N>A

p.Gly27Asp

p.G27D

Q96IU4

protein_coding

tolerated(0.63)

benign(0.075)

TCGA-EY-A1GI-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

ABHD14B

SNV

Missense_Mutation

c.622N>A

p.Gly208Arg

p.G208R

Q96IU4

protein_coding

tolerated(0.49)

benign(0.055)

TCGA-BC-A10R-01

Liver

liver hepatocellular carcinoma

Female

>=65

III/IV

Other, specify in noteschemoembolization

unknown

ABHD14B

SNV

Missense_Mutation

c.328N>T

p.Pro110Ser

p.P110S

Q96IU4

protein_coding

deleterious(0.04)

probably_damaging(1)

TCGA-78-7150-01

Lung

lung adenocarcinoma

Male

<65

I/II

Chemotherapy

carboplatin

ABHD14B

SNV

Missense_Mutation

novel

c.63N>G

p.Phe21Leu

p.F21L

Q96IU4

protein_coding

deleterious(0.01)

benign(0.007)

TCGA-85-A53L-01

Lung

lung squamous cell carcinoma

Male

<65

I/II

Unknown

Page: 1

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1